Zhang Mingfeng, Qi Tong, Yang Lu, Kolarich Daniel, Heisterkamp Nora
Department of Systems Biology, Beckman Research Institute City of Hope, Duarte, CA, United States.
Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
Front Oncol. 2022 Mar 16;12:828041. doi: 10.3389/fonc.2022.828041. eCollection 2022.
Normal early human B-cell development from lymphoid progenitors in the bone marrow depends on instructions from elements in that microenvironment that include stromal cells and factors secreted by these cells including the extracellular matrix. Glycosylation is thought to play a key role in such interactions. The sialyltransferase ST6Gal1, with high expression in specific hematopoietic cell types, is the only enzyme thought to catalyze the terminal addition of sialic acids in an α2-6-linkage to galactose on N-glycans in such cells. Expression of ST6Gal1 increases as B cells undergo normal B-lineage differentiation. B-cell precursor acute lymphoblastic leukemias (BCP-ALLs) with differentiation arrest at various stages of early B-cell development have widely different expression levels of at diagnosis, with high in some but not in other relapses. We analyzed the consequences of increasing ST6Gal1 expression in a diagnosis sample using lentiviral transduction. NSG mice transplanted with these BCP-ALL cells were monitored for survival. Compared to mice transplanted with leukemia cells expressing original ST6Gal1 levels, increased ST6Gal1 expression was associated with significantly reduced survival. A cohort of mice was also treated for 7 weeks with vincristine chemotherapy to induce remission and then allowed to relapse. Upon vincristine discontinuation, relapse was detected in both groups, but mice transplanted with ST6Gal1 overexpressing BCP-ALL cells had an increased leukemia burden and shorter survival than controls. The BCP-ALL cells with higher ST6Gal1 were more resistant to long-term vincristine treatment in an tissue co-culture model with OP9 bone marrow stromal cells. Gene expression analysis using RNA-seq showed a surprisingly large number of genes with significantly differential expression, of which approximately 60% increased mRNAs, in the ST6Gal1 overexpressing BCP-ALL cells. Pathways significantly downregulated included those involved in immune cell migration. However, ST6Gal1 knockdown cells also showed increased insensitivity to chemotherapy. Our combined results point to a context-dependent effect of ST6Gal1 expression on BCP-ALL cells, which is discussed within the framework of its activity as an enzyme with many N-linked glycoprotein substrates.
正常情况下,人类早期B细胞从骨髓中的淋巴祖细胞发育,依赖于该微环境中各种成分发出的指令,这些成分包括基质细胞以及这些细胞分泌的因子,其中也包括细胞外基质。糖基化被认为在这类相互作用中起着关键作用。唾液酸转移酶ST6Gal1在特定造血细胞类型中高表达,是唯一被认为能催化在这类细胞的N聚糖上,以α2-6连接方式将唾液酸末端添加到半乳糖上的酶。随着B细胞经历正常的B系分化,ST6Gal1的表达会增加。在早期B细胞发育的各个阶段出现分化停滞的B细胞前体急性淋巴细胞白血病(BCP-ALL),在诊断时具有广泛不同的ST6Gal1表达水平,在某些复发时表达水平高,而在其他复发时则不然。我们使用慢病毒转导分析了在一个诊断样本中增加ST6Gal1表达的后果。对移植了这些BCP-ALL细胞的NSG小鼠进行生存监测。与移植了表达原始ST6Gal1水平的白血病细胞的小鼠相比,ST6Gal1表达增加与生存率显著降低相关。还有一组小鼠用长春新碱化疗7周以诱导缓解,然后任其复发。停止长春新碱治疗后,两组均检测到复发,但移植了过表达ST6Gal1的BCP-ALL细胞的小鼠白血病负担增加,生存期比对照组短。在与OP9骨髓基质细胞的组织共培养模型中,ST6Gal1水平较高的BCP-ALL细胞对长期长春新碱治疗更具抗性。使用RNA测序进行的基因表达分析显示,在过表达ST6Gal1的BCP-ALL细胞中,有数量惊人的基因表达存在显著差异,其中约60%的mRNA增加。显著下调的通路包括那些参与免疫细胞迁移的通路。然而,敲低ST6Gal1的细胞对化疗也表现出更高的不敏感性。我们的综合结果表明,ST6Gal1表达对BCP-ALL细胞的影响取决于具体情况,这将在其作为具有许多N-连接糖蛋白底物的酶的活性框架内进行讨论。